{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T14:42:18Z","timestamp":1784385738055,"version":"3.55.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["2024-32-0048"],"award-info":[{"award-number":["2024-32-0048"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i), have shown benefits in patient with heart failure (HF), however, adherence remains a significant issue: with only 60% of patients continuing usage beyond a year. This study aims to identify patients at risk of discontinuing SGLT2i and promote its judicious use to reduce hospitalizations and improve cardiovascular outcomes. Using the Korean National Health Insurance Service database, patients diagnosed with HF and diabetes mellitus (n = 1,665,565) between 2013 and 2018 were identified. Among them, 55,694 participants prescribed SGLT2i were enrolled. The primary endpoint included 1) all-cause mortality and 2) SGLT2i-related hospitalization, encompassing incidents such as ketoacidosis, acute kidney injury, urinary tract infections, fall-related fractures, and other unplanned hospitalizations. During the follow-up period (median: 2.3 years; range: 1.2\u20133.6 years), 8,463 participants reached the primary endpoint (25.5 for all-cause death and 39.4 for SGLT2i-related hospitalizations per 1,000 person-years). Independent risk factors for the primary endpoint in multivariate Cox regression and propensity-score matching analyses included age of \u2265 70 years, body mass index (BMI) &lt;18.5 kg\/m<jats:sup>2<\/jats:sup>, body weight &lt;60 kg, anemia, chronic kidney disease, and the use of diuretics. Age (hazard ratio [HR] 1.45, 95% confidence interval [CI]: 1.36\u20131.54), BMI (HR 1.78, 95% CI: 1.29\u20132.45), body weight (HR 1.17, 95% CI: 1.09\u20131.26) and the use of furosemide (HR 1.45, 95% CI: 1.22\u20131.74) (all <jats:italic>p<\/jats:italic>&lt;0.001) were consistent independent risk factors in the propensity score-matched cohort. Having three or more risk factors was associated with an adjusted HR that was 3.04 times higher than cases with no risk factor (95% CI: 2.83\u20133.28, <jats:italic>p<\/jats:italic>&lt;0.001). Old age, low weight or BMI, and the use of diuretics are risk factors that hinder the continuous use of SGLT2i in diabetic patients with HF. Close monitoring for side effects is essential when prescribing SGLT2i, particularly for those with multiple risk factors.<\/jats:p>","DOI":"10.1371\/journal.pone.0314305","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:32:12Z","timestamp":1732559532000},"page":"e0314305","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4079-8219","authenticated-orcid":true,"given":"Minkwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungA","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Woong","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oh-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1793-215X","authenticated-orcid":true,"given":"In Hyun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Kyu","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"15","key":"pone.0314305.ref001","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"HJL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0314305.ref002","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"SD Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0314305.ref003","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"JJV McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0314305.ref004","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0314305.ref005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"SD Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0314305.ref006","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"SD Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0314305.ref007","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"GD Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"pone.0314305.ref008","doi-asserted-by":"crossref","first-page":"1010693","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary","volume":"9","author":"A Mascolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"pone.0314305.ref009","doi-asserted-by":"crossref","first-page":"13472","DOI":"10.1038\/s41598-021-92925-2","article-title":"A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus","volume":"11","author":"J Mukai","year":"2021","journal-title":"Sci Rep"},{"issue":"15","key":"pone.0314305.ref010","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"M Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0314305.ref011","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals","volume":"22","author":"CY Huang","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"pone.0314305.ref012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence","volume":"5","author":"KM Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"1","key":"pone.0314305.ref013","doi-asserted-by":"crossref","first-page":"e3350","DOI":"10.1002\/dmrr.3350","article-title":"Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis","volume":"37","author":"R Ofori-Asenso","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"issue":"36","key":"pone.0314305.ref014","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0314305.ref015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"F Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0314305.ref016","first-page":"e15","article-title":"Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea","volume":"46","author":"J Lee","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"10","key":"pone.0314305.ref017","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/eurheartj\/ehy877","article-title":"Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population","volume":"40","author":"TH Kim","year":"2019","journal-title":"Eur Heart J"},{"issue":"17","key":"pone.0314305.ref018","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/eurheartj\/ehx761","article-title":"Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men","volume":"39","author":"K Kim","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"pone.0314305.ref019","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/eurheartj\/ehy801","article-title":"Reconsidering the cut-off diastolic blood pressure for predicting cardiovascular events: a nationwide population-based study from Korea","volume":"40","author":"YJ Choi","year":"2019","journal-title":"Eur Heart J"},{"key":"pone.0314305.ref020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijcard.2018.08.038","article-title":"Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: A nationwide population-based study","volume":"273","author":"YJ Choi","year":"2018","journal-title":"Int J Cardiol"},{"issue":"12","key":"pone.0314305.ref021","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"V Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"pone.0314305.ref022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"pone.0314305.ref023","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.seminhematol.2015.07.006","article-title":"Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging?","volume":"52","author":"MD Cappellini","year":"2015","journal-title":"Semin Hematol"},{"issue":"3","key":"pone.0314305.ref024","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2011.06.006","article-title":"Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation","volume":"162","author":"H Skali","year":"2011","journal-title":"Am Heart J"},{"issue":"3","key":"pone.0314305.ref025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.36628\/ijhf.2021.0026","article-title":"Using Big Data to Understand Rare Diseases","volume":"3","author":"JB Park","year":"2021","journal-title":"Int J Heart Fail"},{"issue":"7","key":"pone.0314305.ref026","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0314305.ref027","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes","volume":"17","author":"B Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"pone.0314305.ref028","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030876","article-title":"Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure","volume":"11","author":"M Nakagaito","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"pone.0314305.ref029","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"J Liu","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0314305.ref030","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis","volume":"38","author":"RM Goldenberg","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"pone.0314305.ref031","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4103\/2230-8210.139206","article-title":"Medication counselling with sodium glucose transporter 2 inhibitor therapy","volume":"18","author":"S Kalra","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"pone.0314305.ref032","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.2337\/dc16-2793","article-title":"Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995\u20132014","volume":"40","author":"ML Jensen","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"pone.0314305.ref033","doi-asserted-by":"crossref","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"JR Donnan","year":"2019","journal-title":"BMJ Open"},{"issue":"5866","key":"pone.0314305.ref034","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"JF Munro","year":"1973","journal-title":"Br Med J"},{"issue":"5","key":"pone.0314305.ref035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"E Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"pone.0314305.ref036","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2337\/diab.32.5.387","article-title":"Role of glucagon in enhancing ketone body production in ketotic diabetic man","volume":"32","author":"U Keller","year":"1983","journal-title":"Diabetes"},{"issue":"18","key":"pone.0314305.ref037","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial","volume":"142","author":"NA Mordi","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"pone.0314305.ref038","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial","volume":"43","author":"JSS Singh","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"pone.0314305.ref039","doi-asserted-by":"crossref","first-page":"e006977","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in Older Adults Hospitalized for Heart Failure","volume":"13","author":"O Unlu","year":"2020","journal-title":"Circ Heart Fail"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0314305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:32:21Z","timestamp":1732559541000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0314305"}},"subtitle":[],"editor":[{"given":"Peng","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0314305","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}